Get the Stockscreener App
74.81
0.34%
0.25
Pre-market:
75.32
0.51
+0.68%
Cytokinetics Inc stock is traded at $74.81, with a volume of 2.42M.
It is up +0.34% in the last 24 hours and up +15.07% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$74.56
Open:
$74.68
24h Volume:
2.42M
Relative Volume:
1.00
Market Cap:
$10.16B
Revenue:
$105.82M
Net Income/Loss:
$-829.61M
P/E Ratio:
-10.93
EPS:
-6.8429
Net Cash Flow:
$-548.92M
1W Performance:
-2.96%
1M Performance:
+15.07%
6M Performance:
+13.45%
1Y Performance:
+132.84%
1-Day Range:
$73.13
$75.23
1-Week Range:
$72.15
$79.01
52-Week Range:
$29.31
$80.20
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
74.81 | 10.12B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
448.29 | 110.45B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
723.41 | 74.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.81 | 50.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
292.03 | 38.03B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
315.07 | 32.24B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Wells Fargo | Overweight |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Dec-18-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
J.P. Morgan Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $97 - Moomoo
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
CYTK Maintained by JP Morgan -- Price Target Raised to $97.00 - GuruFocus
Growth Investors: Industry Analysts Just Upgraded Their Cytokinetics, Incorporated (NASDAQ:CYTK) Revenue Forecasts By 11% - Yahoo Finance
Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week - 富途牛牛
Cytokinetics (CYTK) Unveils Positive MYQORZO Data at ESC 2026 Co - GuruFocus
One Bay Area company scored $800 million around its heart drug. Here's another targeting the same condition - The Business Journals
Cytokinetics completes $805 million public offering - The Pharma Letter
Cytokinetics presents new data on heart drug aficamten - Investing.com
Cytokinetics presents new data on heart drug aficamten By Investing.com - Investing.com Canada
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026 - Caledonian Record
Heart drug MYQORZO shows long-term safety as HCM burden detailed - Stock Titan
CYTK Maintains by HC Wainwright & Co. -- Price Target Raised to $140 - GuruFocus
1CYTK.MI Stock Chart | CYTOKINETICS INC (BIT:1CYTK) - ChartMill
Can Myqorzo drive growth for Cytokinetics amid competition? - MSN
Cytokinetics (NASDAQ: CYTK) prices $760.2M common stock sale at $71 - Stock Titan
Cytokinetics closes $805 million stock offering By Investing.com - Investing.com Australia
Cytokinetics closes $805 million stock offering - Investing.com
$805M raised as Cytokinetics sells 11.3M shares at $71 each - Stock Titan
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million - marketscreener.com
Press Release: Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $805 Million - Moomoo
CYTK SEC FilingsCytokinetics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Earnings Update: Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Are Boosting Their Estimates - Moomoo
CYTK Maintained by Wells Fargo -- Price Target Raised to $105 - GuruFocus
Cytokinetics, Incorporated 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CYTK) 2026-05-07 - Seeking Alpha
Cytokinetics: Expect Gross Proceeds of Around $700M >CYTK - Moomoo
Cytokinetics (NASDAQ: CYTK) prices 9.859M-share offering to raise $700M - Stock Titan
B. Riley Adjusts Price Target on Cytokinetics to $146 From $108, Maintains Buy Rating - Moomoo
Jefferies raises Cytokinetics stock price target on trial results - Investing.com UK
Jefferies raises Cytokinetics stock price target on trial results By Investing.com - Investing.com Australia
Cytokinetics Is Maintained at Overweight by Wells Fargo - Moomoo
Earnings Beat: Cytokinetics, Incorporated (NASDAQ:CYTK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
Cytokinetics Price Target Raised to $108.00/Share From $98.00 by Stifel - Moomoo
Why is Cytokinetics (CYTK) down 0.8% since last earnings report? - MSN
Cytokinetics Prices Upsized $700 Million Share Offering - marketscreener.com
Cytokinetics prices upsized $700M equity raise at $71 per share - MSN
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock - The Manila Times
Cytokinetics prices $700 million stock offering at $71 per share By Investing.com - Investing.com Australia
Cytokinetics prices $700 million stock offering at $71 per share - Investing.com
Cytokinetics Announces Pricing of $700 Million Public Offering of Common Stock - Quiver Quantitative
Cytokinetics prices public offering of 9.8 mln shares at $71/share - marketscreener.com
Cytokinetics prices nearly 9.9M-share sale at $71 a share - Stock Titan
Cytokinetics Offering Expected to Close May 8 >CYTK - Moomoo
CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch - TradingView
RBC Adds Speculative Risk to Outperform Rating on Cytokinetics, Lifts Price Target to $119 From $101 - Moomoo
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $101 to $136 - Moomoo
Cytokinetics' Rapid Growth of Myqorzo not Fully Priced in by Investors, RBC Says - marketscreener.com
Cytokinetics rallies on late-stage Myqorzo data, strengthening sales outlook - S&P Global
FMR LLC increases stake in Cytokinetics (NASDAQ: CYTK) to 9.0% - Stock Titan
Truist raises Cytokinetics stock price target on positive trial data By Investing.com - Investing.com South Africa
Cytokinetics Stock Rallies After Pivotal Heart Disease Study Hits Dual Primary Endpoints - Sahm
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):